FDA/CE Advantage Leverage MammaPrint and BluePrint's FDA clearance and CE marking to target multinational healthcare systems and insurers seeking proven, guideline-supported genomic tests for early-stage breast cancer.

Guideline Uptake capitalize on NCCN and ASCO alignments recognizing MammaPrint to drive adoption among oncologists who follow clinical practice updates for personalized chemotherapy decisions.

Diversity Outcomes Highlight genomic risk and treatment disparity data presented at ASCO to engage payers and providers focused on equity and real-world outcomes, opening conversations for broader test coverage and inclusion programs.

Expanded Evidence Promote across-trial and real-world evidence including MINDACT and I-SPY 2 findings to support expansion into HR+/HER2- and TN breast cancer subtypes, increasing total addressable market.

Strategic Partnerships Target research hospitals, cancer centers, and integrated delivery networks with precision oncology portfolios to cross-sell MammaPrint/BluePrint alongside other genomic assays and decision-support tools.